Ascentage Pharma Group International has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. Dr. Yang Dajun serves as Executive Director and Chairman. Non-executive Directors include Dr. Wang Shaomeng and Dr. Lu Simon Dazhong. The Board also comprises Independent Non-executive Directors: Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky (Lead Independent Non-executive Director), Ms. Marina S. Bozilenko, Dr. Debra Yu, and Marc E. Lippman, MD. Committee memberships are as follows: - Mr. Ye Changqing is Chairman of the Audit Committee and a member of the Remuneration Committee. - Dr. Lu Simon Dazhong is a member of the Audit Committee. - Ms. Marina S. Bozilenko is a member of the Audit Committee. - Mr. Ren Wei chairs the Remuneration Committee and is a member of the Nomination Committee. - Dr. Debra Yu chairs the Nomination Committee and is a member of the Remuneration Committee. - Dr. David Sidransky chairs the Research and Development Committee and is a member of the Nomination Committee. - Marc E. Lippman, MD is Chairman of the Research and Development Committee and a member of the Nomination Committee. - Dr. Wang Shaomeng is a member of the Research and Development Committee. The company maintains three board committees: Audit, Remuneration, and Nomination, as well as a Research and Development Committee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251230-11971806), on December 30, 2025, and is solely responsible for the information contained therein.